GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (STU:1U5) » Definitions » 12-1 Month Momentum %

WAVE Life Sciences (STU:1U5) 12-1 Month Momentum % : 75.45% (As of Apr. 13, 2025)


View and export this data going back to 2018. Start your Free Trial

What is WAVE Life Sciences 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2025-04-13), WAVE Life Sciences's 12-1 Month Momentum % is 75.45%.

The industry rank for WAVE Life Sciences's 12-1 Month Momentum % or its related term are showing as below:

STU:1U5's 12-1 Month Momentum % is ranked better than
90.44% of 1444 companies
in the Biotechnology industry
Industry Median: -23.6 vs STU:1U5: 75.45

Competitive Comparison of WAVE Life Sciences's 12-1 Month Momentum %

For the Biotechnology subindustry, WAVE Life Sciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WAVE Life Sciences's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's 12-1 Month Momentum % falls into.


;
;

WAVE Life Sciences  (STU:1U5) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WAVE Life Sciences  (STU:1U5) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


WAVE Life Sciences 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


WAVE Life Sciences Business Description

Traded in Other Exchanges
Address
7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

WAVE Life Sciences Headlines

No Headlines